NVO Novo Nordisk A/S
Healthcare$44.19-1.71%ClosedMarket Cap: $196.37B
As of 2026-05-26
Valuation
P/E (TTM)
10.48
PEG
1.12
P/B
6.32
P/S
3.92
EV/EBITDA
7.66
DCF Value
$93.04
FCF Yield
2.4%
Div Yield
4.0%
Margins & Returns
Gross Margin
81.8%
Operating Margin
45.3%
Net Margin
37.2%
ROE
66.4%
ROA
21.8%
ROIC
32.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $96.82B | 86.0% | $59.62B | $48.56B | $— | $0.92 |
| Q4 null | $79.14B | 80.9% | $31.74B | $26.89B | $— | — |
| FY null | $309.06B | 81.0% | $127.66B | $102.43B | $— | $1.23 |
| Q3 null | $74.98B | 76.1% | $23.68B | $20.01B | $— | $0.41 |
| Q2 null | $76.86B | 83.3% | $33.45B | $26.50B | $— | $0.82 |
| Q1 null | $78.09B | 83.5% | $38.79B | $29.03B | $— | $0.82 |
| Q4 null | $85.68B | 84.8% | $36.74B | $28.23B | $— | — |
| FY null | $290.40B | 84.7% | $128.34B | $100.99B | $— | $1.03 |
| Q3 null | $71.31B | 84.1% | $33.82B | $27.30B | $— | $0.36 |
| Q2 null | $68.06B | 84.9% | $25.93B | $20.05B | $— | — |
| Q1 null | $65.35B | 84.8% | $31.85B | $25.41B | $— | $0.66 |
| Q4 2023 | $65.86B | 84.8% | $26.77B | $21.96B | $4.91 | — |